Plant Name: Stephania pierrei
Taxonomic Information:
Plant ID: NPO22151
Plant Latin Name: Stephania pierrei
Taxonomy Genus: Stephania
Taxonomy Family: Menispermaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
581472-1
Used in Medicines:
Country/Region:
ThailandTraditional Medicine System:
Geographical Distribution:
Thailand; Vietnam; Cambodia; Laos
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR1A; DRD1; | |
| PTPN1; | |
| F3; RAD52; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0042053; regulation of dopamine metabolic process | 9.151E-06 | 9.963E-02 | DRD1, HTR1A |
| BP | GO:0007610; behavior | GO:0001662; behavioral fear response | 2.325E-05 | 1.154E-01 | DRD1, HTR1A |
| BP | GO:0008152; metabolic process | GO:0018958; phenol-containing compound metabolic process | 1.597E-04 | 3.964E-01 | DRD1, HTR1A |
| MF | GO:0060089; molecular transducer activity | GO:0030594; neurotransmitter receptor activity | 3.120E-04 | 5.636E-01 | DRD1, HTR1A |
| CC | GO:0044464; cell part | GO:0097443; sorting endosome | 1.552E-03 | 6.898E-01 | PTPN1 |
| MF | GO:0060089; molecular transducer activity | GO:0001588; dopamine neurotransmitter receptor activity, coupled via Gs | 1.035E-03 | 6.898E-01 | DRD1 |
| MF | GO:0060089; molecular transducer activity | GO:0004888; transmembrane signaling receptor activity | 2.477E-03 | 8.281E-01 | DRD1, F3, HTR1A |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 2.844E-03 | 8.610E-01 | HTR1A |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 3.361E-03 | 8.610E-01 | DRD1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.658E-04 | 1.673E-02 | HTR1A, DRD1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.859E-03 | 1.673E-02 | HTR1A, DRD1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.219E-02 | 3.834E-02 | DRD1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 1.664E-02 | 3.834E-02 | DRD1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.837E-02 | 3.834E-02 | PTPN1 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 2.058E-02 | 3.834E-02 | HTR1A |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.500E-02 | 3.834E-02 | F3 |
| 09150 Organismal Systems | 09151 Immune system | hsa04610 | Complement and coagulation cascades | 1.960E-02 | 3.834E-02 | F3 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.696E-02 | 3.834E-02 | PTPN1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.769E-02 | 3.834E-02 | HTR1A |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR1A; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR1A; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; HTR1A; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| NA: NA | Social phobia | NA | HTR1A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; HTR1A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| NA: NA | Episode | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR1A; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; HTR1A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
